Literature DB >> 32493697

FDA Approves Selpercatinib; Pralsetinib May Soon Follow.

.   

Abstract

The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non-small cell lung cancer (NSCLC) and certain types of thyroid cancer. Another RET inhibitor, pralsetinib, has been submitted for approval to treat NSCLC. Both drugs have shown effectiveness in treating brain metastases. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32493697     DOI： 10.1158/2159-8290.CD-NB2020-052

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

Review 1.  Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.

Authors:  Lu Zhao; Qingyun Mei; Yongchao Yu; Na Wang; Dou Zhang; Dongying Liao; Jinhui Zuo; Hongxia Xie; Yingjie Jia; Fanming Kong
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

Review 2.  New Horizons: Emerging Therapies and Targets in Thyroid Cancer.

Authors:  Matthew D Ringel
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

3.  Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.

Authors:  Mimi I Hu; Steven G Waguespack; Chrysoula Dosiou; Paul W Ladenson; Masha J Livhits; Lori J Wirth; Peter M Sadow; Jeffrey F Krane; Brendan C Stack; Mark E Zafereo; Syed Z Ali; Steven P Weitzman; Yangyang Hao; Joshua E Babiarz; Giulia C Kennedy; Richard T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.